HIV and Boceprevir Drug Interactions

Phase III clinical trials tend to enroll carefully selected patients who have few or mild-to-moderate pre-existing health conditions. In practice, once a drug is licensed, a wide variety of patients, some of whom may have multiple health conditions, may receive a new drug. One such pre-existing condition is HIV co-infection. As HIV-positive people will most likely be taking potent combination anti-HIV therapy (commonly called ART or HAART), it is essential to study potential interactions between drugs used for HIV and drugs used for HCV.

World-renowned pharmacologist David Burger, Ph.D., has assembled and reviewed data on many potential interactions that could occur between different drugs. Here is a summary of recent research that he presented.

Boceprevir -- Impact on HIV Protease Inhibitors

Advertisement

In experiments used to assess interactions between drugs, here are the main findings:

levels of atazanavir-ritonavir fell by 35% when used with boceprevir

levels of lopinavir-ritonavir (in Kaletra) fell by 34% when used with boceprevir

levels of darunavir-ritonavir fell by 44% when used with boceprevir

These changes are so great that Dr. Burger notes that boceprevir should not be used with these HIV drugs.

Raltegravir

Levels of this drug increased by 1% when used with boceprevir.

Non-Nuke Interactions

Boceprevir reduced etravirine levels by 23%.

Efavirenz reduced boceprevir levels by 19% -- these should not be used together.

Effect of HIV Drugs on Boceprevir

In experiments on people, the following changes occurred:

atazanavir-ritonavir reduced boceprevir levels by 5%

lopinavir-ritonavir reduced boceprevir levels by 34%

darunavir-ritonavir reduced boceprevir levels by 32%

etravirine reduced boceprevir levels by 10%.

Bocepravir Drug Interaction Summary

Dr. Burger recommended that the following courses of action be taken by doctors who are contemplating prescribing boceprevir to people who are co-infected with HIV and HCV:

tenofovir increases boceprevir levels by 8% -- these drugs may be used together

etravirvine may be used with boceprevir

raltegravir may be used with boceprevir

The following drugs should not be used with boceprevir:

atazanavir-ritonavir

lopinavir-ritonavir

darunavir-ritonavir

efavirenz reduces boceprevir levels by 19% -- these should not be used together

Each person will likely be taking several other drugs to treat complications of HCV (or HIV infection), therefore much more information about drug interactions is needed. Until the results of large clinical trials conducted by the ACTG and ANRS are completed and consensus has emerged about which drugs to use, we urge physicians who are contemplating prescribing these or other therapies to seek guidance from regulatory authorities, consult the necessary product monographs or speak with other experts, particularly pharmacologists and other specialists who are experienced in treating co-infected patients.

Reference

Burger DM. Interactions between antiretrovirals and direct acting antivirals. In: Program and abstracts of the 8th International Workshop on HIV and Hepatitis Co-infection, 30 May - 1 June 2012, Madrid, Spain.

(Please note: Your name and comment will be public, and may even show up in Internet search results. Be careful when providing personal information! Beforeadding your comment, please read TheBody.com's Comment Policy.)

TheBodyPRO.com is a service of Remedy Health Media, LLC, 750 3rd Avenue, 6th Floor, New York, NY 10017. TheBodyPRO.com and its logos are trademarks of Remedy Health Media, LLC, and its subsidiaries, which owns the copyright of TheBodyPRO.com's homepage, topic pages, page designs and HTML code. General Disclaimer: TheBodyPRO.com is designed for educational purposes only and is not engaged in rendering medical advice or professional services. The information provided through TheBodyPRO.com should not be used for diagnosing or treating a health problem or a disease. It is not a substitute for professional care. If you have or suspect you may have a health problem, consult your health care provider.